Tumor-Infiltrating Lymphocyte Secretion of IL-6 Antagonizes Tumor-Derived TGF-β1 and Restores the Lymphokine-Activated Killing Activity

Journal of Immunology

Volumn 172, Issue 3, 2004, Pages 1508-1514

  Hsiao, Ya Wen ^a   Liao, Kuang Wen ^a,b   Hung, Shao Wen ^a   Chu, Rea Min ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NONE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANIMAL VENEREAL TUMOR; ARTICLE; CANCER IMMUNOTHERAPY; CANINE TRANSMISSIBLE VENEREAL TUMOR; CELL ACTIVATION; CELL ISOLATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DOG; FEMALE; IMMUNE RESPONSE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

EID: 1642566826     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.3.1508     Document Type: Article

References (37)

1. Halak, B. K., H. C. Maguire, Jr., and E. C. Lattime. 1999. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 59:911.
2. Pasche, B. 2001. Role of transforming growth factor β in cancer. J. Cell. Physiol. 186:153.
3. Kim, I. Y., H. J. Ahn, D. J. Zelner, J. W. Shaw, J. A. Sensibar, J. H. Kim, M. Kato, and C. Lee. 1996. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res. 56:44.
4. Reiss, M. 1999. TGF-β and cancer. Microbes Infect. 1:1327.
5. Gold, L. I. 1999. The role for transforming growth factor-β (TGF-β) in human cancer. Crit. Rev. Oncog. 10:303.
6. Gilboa, E. 1999. How tumors escape immune destruction and what we can do about it. Cancer Immunol. Immunother. 48:382.
7. Hsiao, Y.-W., K.-W. Liao, S.-W. Hung, and R.-M. Chu. 2002. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Ver. Immunol. Immunopathol. 87:19.
8. Nie, Y., G. Yang, Y. Song, X. Zhao, C. So, J. Liao, L. D. Wang, and C. S. Yang. 2001. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22:1615.
9. Seliger, B., A. Hohne, D. Jung, M. Kallfelz, A. Knuth, E. Jaeger, H. Bernhard, F. Momburg, R. Tampe, and C. Huber. 1997. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp. Hematol. 25:608.
10. Wiendl, H., M. Mitsdoerffer, V. Hofmeister, J. Wischhusen, A. Bornemann, R. Meyermann, E. H. Weiss, A. Melms, and M. Weller. 2002. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 168:4772.
11. Ikeda, H., B. Lethe, F. Lehmann, N. van Baren, J. F. Baurain, C. de Smet, H. Chambost, M. Vitale, A. Moretta, T. Boon, and P. G. Coulie. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199.
12. Bird, C. H., V. R. Sutton, J. Sun, C. E. Hirst, A. Novak, S. Kumar, J. A. Trapani, and P. I. Bird. 1998. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol. Cell. Biol. 18:6387.
13. Lehmann, C., M. Zeis, N. Schmitz, and L. Uharek. 2000. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 96:594.
14. Groh, V., R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein, and T. Spies. 1999. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96:6879.
15. Straus, S. E., E. S. Jaffe, J. M. Puck, J. K. Dale, K. B. Elkon, A. Rosen-Wolff, A. M. Peters, M. C. Sneller, C. W. Hallahan, J. Wang, et al. 2001. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98:194.
16. Lee, K. H., M. C. Panelli, C. J. Kim, A. I. Riker, M. P. Bettinotti, M. M. Roden, P. Fetsch, A. Abati, S. A. Rosenberg, and F. M. Marincola. 1998. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 161:4183.
17. Sarris, A. H., K. O. Kliche, P. Pethambaram, A. Preti, S. Tucker, C. Jackow, O. Messina, W. Pugh, F. B. Hagemeister, P. McLaughlin, et al. 1999. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol. 10:433.
18. Kharkevitch, D. D., D. Seito, G. C. Balch, T. Maeda, C. M. Balch, and K. Itoh. 1994. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int. J. Cancer 58:317.
19. Ortegel, J. W., E. D. Staren, L. P. Faber, W. H. Warren, and D. P. Braun. 2002. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 36:17.
20. Ohta, K., S. Yamagami, A. W. Taylor, and J. W. Streilein. 2000. IL-6 antagonizes TGF-β and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest. Opthalmol. Visual Sci. 41:2591.
21. Cao, X., Q. Wang, D. W. Ju, Q. Tao, and J. Wang. 1999. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene. J. Exp. Clin. Cancer Res. 18:191.
22. Liao, K.-W., S.-W. Hung, Y.-W. Hsiao, M. Bennett, and R.-M. Chu. 2003. Depletion of peripheral blood B lymphocytes induced by local inoculation of canine transmissible venereal tumor cells. Vet. Immunol. Immunopathol. 92:149.
23. Trail, P. A., and T. J. Yang. 1985. Canine transmissible venereal sarcoma: quantitation of T-lymphocyte subpopulations during progressive growth and spontaneous tumor regression. J. Natl. Cancer Inst. 74:461.
24. Chu, R.-M., J. Y. Lin, C. G. Liu, S. Y. Yang, W. C. Hseuh, Y.-W. Hsiao, S. W. Hong, H. N. Pao, and K.-W. Liao. 2001. Proliferation characteristics of canine transmissible venereal tumor. Anticancer Res. 21:4017.
25. Geldhof, A. B., K. De Meyer, P. De Baetselier, and H. Verschueren. 2002. Morphometric analysis of cytolysis in cultured cell monolayers: a simple and versatile method for the evaluation of the cytotoxic activity and the fate of LAK cells. Lab. Invest. 82:105.
26. Whiteside, T. L., S. Miescher, J. Hurlimann, L. Moretta, and V. von Fliedner. 1986. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int. J. Cancer 37:803.
27. Rabinowich, H., R. Cohen, I. Bruderman, Z. Steiner, and A. Klajman. 1987. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 47:173.
28. Wahl, S. M. 1994. Transforming growth factor β: the good, the bad, and the ugly. J. Exp. Med. 180:1587.
29. Dubois, C. M., M. H. Laprise, F. Blanchette, L. E. Gentry, and R. Leduc. 1995. Processing of transforming growth factor β1 precursor by human furin convertase. J. Biol. Chem. 270:10618.
30. Miyazono, K., J. Thyberg, and C. H. Heldin. 1992. Retention of the transforming growth factor-β1 precursor in the Golgi complex in a latent endoglycosidase H-sensitive form. J. Biol. Chem. 267:5668.
31. Hirano, T., S. Akira, T. Taga, and T. Kishimoto. 1990. Biological and clinical aspects of interleukin 6. Immunol. Today 11:443.
32. Akira, S., T. Hirano, T. Taga, and T. Kishimoto. 1990. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4:2860.
33. Rabinowich, H., P. Sedlmayr, R. B. Herberman, and T. L. Whiteside. 1993. Response of human NK cells to IL-6 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor-α/β secretion. J. Immunol. 150:4844.
34. Scheid, C., R. Young, R. McDermott, L. Fitzsimmons, J. H. Scarffe, and P. L. Stern. 1994. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase 1 clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol. Immunother. 38:119.
35. + cells. Cell. Immunol. 144:1.
36. Steiner, T., U. Junker, H. Wunderlich, and J. Schubert. 1999. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6? Anticancer Res. 19:1533.
37. La Flamme, A. C., and E. J. Pearce. 1999. The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses. J. Immunol. 162:5829.